Hebei Changshan Biochemical Pharmaceutical (300255) Fundamentals 2026 — Revenue Analysis | SniperIQ
Hebei Changshan Biochemical Pharmaceutical (300255) is a CN-listed Healthcare company in Biotechnology with a market capitalization of ¥26.2B, trading at ¥28.46 on the SHZ. This SniperIQ fundamentals page covers Hebei Changshan Biochemical Pharmaceutical's valuation, profitability (net margin -40.8%), revenue (¥875M in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Hebei Changshan Biochemical Pharmaceutical's market cap?
Hebei Changshan Biochemical Pharmaceutical (300255) has a market capitalization of approximately ¥26.2B, trading at ¥28.46 on the SHZ. Market cap moves with the live share price.
What is Hebei Changshan Biochemical Pharmaceutical's P/E ratio?
Hebei Changshan Biochemical Pharmaceutical's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 21.6x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Hebei Changshan Biochemical Pharmaceutical?
Hebei Changshan Biochemical Pharmaceutical runs a net profit margin of -40.8%, a gross margin of 16.9%, and an operating margin of -37.7%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Hebei Changshan Biochemical Pharmaceutical generate?
Hebei Changshan Biochemical Pharmaceutical reported revenue of ¥875M for fiscal year 2025, with net income of -¥358M and earnings per share (EPS) of -0.39. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Hebei Changshan Biochemical Pharmaceutical pay a dividend?
Hebei Changshan Biochemical Pharmaceutical does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Is Hebei Changshan Biochemical Pharmaceutical financially healthy?
Hebei Changshan Biochemical Pharmaceutical carries a debt-to-equity ratio of 1.93x and a current ratio of 0.74x, with a market beta of 0.35. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Hebei Changshan Biochemical Pharmaceutical a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Hebei Changshan Biochemical Pharmaceutical (300255) the key facts are: market cap ¥26.2B, revenue ¥875M, 52-week range 21.19-71.71. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Hebei Changshan Biochemical Pharmaceutical's full fundamentals live
Get Hebei Changshan Biochemical Pharmaceutical's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.